ATE373016T1 - Induktion von immunologischer toleranz gegen einen therapeutischen antikörper durch varianten des therapeutischen antikörpers - Google Patents

Induktion von immunologischer toleranz gegen einen therapeutischen antikörper durch varianten des therapeutischen antikörpers

Info

Publication number
ATE373016T1
ATE373016T1 AT97905226T AT97905226T ATE373016T1 AT E373016 T1 ATE373016 T1 AT E373016T1 AT 97905226 T AT97905226 T AT 97905226T AT 97905226 T AT97905226 T AT 97905226T AT E373016 T1 ATE373016 T1 AT E373016T1
Authority
AT
Austria
Prior art keywords
therapeutic antibody
antibody
immunological tolerance
variants
induction
Prior art date
Application number
AT97905226T
Other languages
German (de)
English (en)
Inventor
Herman Waldmann
Lisa Gilliland
Masahide Tone
Mark Frewin
Louise Walsh
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of ATE373016T1 publication Critical patent/ATE373016T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97905226T 1996-02-20 1997-02-20 Induktion von immunologischer toleranz gegen einen therapeutischen antikörper durch varianten des therapeutischen antikörpers ATE373016T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9603507.6A GB9603507D0 (en) 1996-02-20 1996-02-20 Antibody variants

Publications (1)

Publication Number Publication Date
ATE373016T1 true ATE373016T1 (de) 2007-09-15

Family

ID=10789047

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97905226T ATE373016T1 (de) 1996-02-20 1997-02-20 Induktion von immunologischer toleranz gegen einen therapeutischen antikörper durch varianten des therapeutischen antikörpers

Country Status (11)

Country Link
US (2) US20020048578A1 (enExample)
EP (1) EP0970127B1 (enExample)
JP (1) JP4574750B2 (enExample)
AT (1) ATE373016T1 (enExample)
AU (1) AU723366B2 (enExample)
CA (1) CA2246715C (enExample)
DE (1) DE69738138T2 (enExample)
ES (1) ES2294793T3 (enExample)
GB (1) GB9603507D0 (enExample)
NZ (1) NZ331299A (enExample)
WO (1) WO1997031024A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0859841B1 (en) * 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
JP4334866B2 (ja) 2000-10-09 2009-09-30 アイシス イノヴェイション リミテッド 治療用抗体
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20040109855A1 (en) * 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
KR20060002896A (ko) * 2003-03-31 2006-01-09 기린 비루 가부시키가이샤 항 ｃｄ52 항체에 의한 조절성 ｔ 세포 분화 유도ㆍ증식방법 및 그를 위한 의약 조성물
NZ550815A (en) * 2004-05-19 2009-04-30 Immunocore Ltd Method of improving T cell receptors
AU2006226192A1 (en) * 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US20100197896A1 (en) * 2007-05-16 2010-08-05 Leung Shui-On Functional humanization of complementarity determining regions (cdrs)
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
MX2011012047A (es) 2009-05-13 2011-12-14 Genzyme Corp Inmunoglobulinas humanas anti-cd52.
NZ596603A (en) 2009-05-29 2013-07-26 Morphosys Ag A collection of antibodies or fragments having properties relevant to developability
EP2640742B1 (en) 2010-11-19 2018-08-15 MorphoSys AG A collection of antibody sequences its use
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
US9494597B2 (en) * 2012-04-02 2016-11-15 Ab Biosciences, Inc. Human control antibodies and uses therefor
PE20150605A1 (es) 2012-04-27 2015-05-28 Cytomx Therapeutics Inc Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
US20160120158A1 (en) * 2014-11-03 2016-05-05 The Johns Hopkins University Compositions and methods for the study and treatment of acute kidney injury
WO2016196935A1 (en) 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
EP3962926A4 (en) 2019-04-30 2022-11-23 Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center COMPOSITIONS AND METHODS FOR MODULATION OF ANTIBODY ACTIVITY

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
CA1339198C (en) * 1988-02-12 1997-08-05 Gregory Paul Winter Antibodies to the antigen campath-1
US5858725A (en) 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
KR100264218B1 (ko) * 1991-10-15 2000-08-16 그레이엄 브레레톤 관절의 T-세포 매개 염증의 치료용 CDw52-특이 항체
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method

Also Published As

Publication number Publication date
US8440190B2 (en) 2013-05-14
US20020048578A1 (en) 2002-04-25
AU723366B2 (en) 2000-08-24
EP0970127B1 (en) 2007-09-12
JP4574750B2 (ja) 2010-11-04
CA2246715C (en) 2008-08-05
GB9603507D0 (en) 1996-04-17
US20060018898A1 (en) 2006-01-26
CA2246715A1 (en) 1997-08-28
WO1997031024A1 (en) 1997-08-28
EP0970127A1 (en) 2000-01-12
JP2000506723A (ja) 2000-06-06
DE69738138T2 (de) 2008-06-05
NZ331299A (en) 2000-05-26
AU1885197A (en) 1997-09-10
DE69738138D1 (de) 2007-10-25
ES2294793T3 (es) 2008-04-01

Similar Documents

Publication Publication Date Title
DE69738138D1 (de) Induktion von immunologischer Toleranz gegen einen therapeutischen Antikörper durch Varianten des therapeutischen Antikörpers
ATE415423T1 (de) Immunisierungstherapie zur behandlung von atherosklerose
AT500379B1 (de) Tau-proteine
DE69433406T2 (de) Antikörper gegen cd40
ATE513563T1 (de) Therapeutische und toleranz-induzierende antikörper
DE60236646D1 (de) Anti-VEGF-2 Antikörper
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
ATE320448T1 (de) Gereinigte primate clta-8 antigene und verwandte reagenzien
ATE414104T1 (de) Fragmente des menschlichen choriogonadotropin (hcg) als immunregulator
CY1109817T1 (el) Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
DE60238533D1 (de) Nicht-depletierender Antikörper TRX-1 gegen CD4 und dessen Verwendungen
DE69530844D1 (de) Verfahren und substanzen gegen protozoen
EP1411962A4 (en) TREATMENT OF PANCREATIC CANCER WITH A MONOCLONAL ANTIBODY
PT812206E (pt) Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
EA200200974A1 (ru) Моноклональные антитела к рецептору лпнп человека, их получение и применение
DE69636527D1 (de) Antigenes protein aus malassezia
ATE108832T1 (de) Verwendung von monoklonalen antikörpern gegen b2- mikroglobulin.
ATE136469T1 (de) Neue verwendung eines monoklonalen antikörpers
RU96123360A (ru) Способ лечения сепсиса у новорожденных

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties